Clinical Trial Finder Search Results

About the Fight CRC Clinical Trial Finder

This Trial Finder is a one-stop place to find and learn more about high-impact clinical trials for colorectal cancer patients with advanced colon or rectal cancer. Originally created by the late Dr. Tom Marsilje as a curated spreadsheet of trials, the FightCRC’s Trial Finder is a resource to find research studies that are open in your geography, and for which you may be eligible. The current data is now for metastatic, stage IV patients with both MSS and MSI-H status. The list of trials here is sourced from the ClinicalTrials.gov website and curated with Comments and Helpful Links. The searches can be focused on immunotherapy-centered trials and narrowed to studies enrolling patients who already have received immunotherapies.

Medical Disclaimer

The information contained in this website is not intended to recommend the self management of health problems, medical conditions or wellness. It is not intended to endorse or recommend any particular type of medical treatment, physician or treatment facility. Should any reader have any health care related questions, promptly call or consult your physician or healthcare provider. The information contained in this website should NOT be used by any reader to disregard medical and/or health related advice or provide a basis to delay consultation with a physician or a qualified healthcare provider. Fight Colorectal Cancer disclaims any liability based on information provided in this website.

Location

MS status

Recruitment Status

Phase

Drugs

Prior Immunotherapy Allowed

NCT ID

Title key word search

Date Trial Added

From To

View:

Compact Expanded

PDF Excel CSV

NCT ID	Title	Phase	Date Added	Location	Prior IO Allowed	CRC-directed	Status	Drugs	Tags
NCT ID NCT03977090	TitleGeptanolimab(GB226) Combined With Fruquintinib in the Treatment of Metastatic Colorectal Cancer	Phase Phase 1	Date Added 2019-06-06	Location China	Prior IO Allowed No	CRC-directed Yes	Status Recruiting	Drugs Fruquintinib, Geptanolimab Injection, Elunate	Tags MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT05319314	TitleGCC19CART for Patients With Metastatic Colorectal Cancer	Phase Phase 1	Date Added 2022-04-08	Location California, United States Colorado, United States Massachusetts, United States Michigan, United States Texas, United States	Prior IO Allowed Yes	CRC-directed Yes	Status Recruiting	Drugs GCC19CART	Tags MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT04866862	TitleFruquitinib Combined With Camrelizumab in Non MSI-H/dMMR Refractory Colorectal Cancer	Phase Phase 2	Date Added 2021-04-30	Location China	Prior IO Allowed No	CRC-directed Yes	Status Recruiting	Drugs Combination of Fruquintinib and Camrelizumab	Tags MSS/ MMRp
NCT ID NCT05627635	TitleFOLFOX and Bevacizumab in Combination With Botensilimab and Balstilimab (3B-FOLFOX) for the Treatment of Microsatellite Stable (MSS) Metastatic Colorectal Cancer	Phase Phase 1, Phase 2	Date Added 2022-11-25	Location California, United States	Prior IO Allowed No	CRC-directed Yes	Status Active, not recruiting	Drugs Balstilimab, Botensilimab, fluorouracil, Leucovorin Calcium, oxaliplatin	Tags MSS/ MMRp
NCT ID NCT06801665	TitleFMT+ QL1706+bevacizumab+ XELOX As First-line Treatment for Advanced MSS-type Colon Cancer with Liver Metastasis	Phase Phase 2	Date Added 2025-01-30	Location	Prior IO Allowed No	CRC-directed Yes	Status Not yet recruiting	Drugs	Tags MSS/ MMRp
NCT ID NCT05277051	TitleFirst-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors	Phase Phase 1	Date Added 2022-03-14	Location California, United States North Carolina, United States Oklahoma, United States Pennsylvania, United States Texas, United States Utah, United States Australia Canada China France Japan Korea, Republic of Spain United Kingdom	Prior IO Allowed Yes	CRC-directed Yes	Status Recruiting	Drugs Dostarlimab, GSK4381562	Tags MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT03860272	TitleFc-Engineered Anti-CTLA-4 Monoclonal Antibody Botensilimab in Advanced Cancer	Phase Phase 1	Date Added 2019-03-01	Location Arizona, United States California, United States Colorado, United States Connecticut, United States Florida, United States Massachusetts, United States New York, United States Oregon, United States Texas, United States United Kingdom	Prior IO Allowed Yes	CRC-directed Yes	Status Active, not recruiting	Drugs Balstilimab, Botensilimab	Tags MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT05409417	TitleExploratory Study on Combined Conversion Immunotherapy for Liver Metastasis of MSS Type Initial Unresectable Colorectal Cancer Based on Gene Status	Phase Phase 2	Date Added 2022-06-08	Location China	Prior IO Allowed Yes	CRC-directed Yes	Status Unknown status	Drugs Bevacizumab, cetuximab, FOLFOX, Tislelizumab, XELOX	Tags MSS/ MMRp
NCT ID NCT03795311	TitleEvaluation of the Efficacy and the Safety of FOLFIRINOX3 Bevacizumab Treatment in Patients With Colorectal Cancer (FOLFIRINOX 3)	Phase Phase 1, Phase 2	Date Added 2019-01-07	Location France	Prior IO Allowed No	CRC-directed Yes	Status Active, not recruiting	Drugs FOLFIRINOX Bevacizumab	Tags MSS/ MMRp
NCT ID NCT04895722	TitleEvaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008)	Phase Phase 2	Date Added 2021-05-20	Location Florida, United States Georgia, United States Illinois, United States New York, United States Pennsylvania, United States Tennessee, United States Texas, United States Washington, United States Belgium Canada Colombia Costa Rica Denmark Estonia France Germany Greece Guatemala Hungary Italy Korea, Republic of Lithuania Netherlands Poland Romania Russian Federation Spain Turkey United Kingdom	Prior IO Allowed No	CRC-directed Yes	Status Active, not recruiting	Drugs Favezelimab/Pembrolizumab, Pembrolizumab/Quavonlimab, pembrolizumab/vibostolimab coformulation, Keytruda	Tags MSI-H/ MMRd

Showing 161 to 170 of 299 entries